Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy
Glytec's patented eGlycemic Management System (eGMS) will be a focal point of the health system's diabetes service line, offering clinicians a set of tools, technologies and processes proven to achieve full adoption of basal-bolus insulin therapy
, the standard of care and best practice endorsed by the American Diabetes Association and American Association of Clinical Endocrinologists.
Basal-bolus insulin therapy
and glycemic control in adult patients with type 2 diabetes mellitus: A review of the literature.
It will be developed and validated initially for people with diabetes on basal-bolus insulin therapy
, but the underlying approach can be adapted to other chronic diseases.
Randomized Study of Basal-Bolus Insulin Therapy
in the Inpatient Management of Patients with Type 2 Diabetes (RABBIT 2 Trial).
The subgroup of patients receiving basal-bolus insulin therapy
at baseline and at Week 12 allowed a 'like with like' comparison of changes in insulin dosing to be made.
A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy
(Kuma moto Insulin Degludec Observational study).
Blood glucose values of patients who received bolus-only insulin therapy were compared to glucose values for patients who received basal-bolus insulin therapy
The risk of hypoglycemia is a major barrier to initiating basal-bolus insulin therapy
The results of this study suggest that patients previously treated with insulin may benefit more from basal-bolus insulin therapy
, whereas insulin-naive patients may benefit equally with both regimens, although biphasic insulin may be more convenient.